DIA DIRECT: Developing Vaccines for COVID-19

On-Demand Webinar

There are several potential COVID-19 vaccines currently in the development pipeline, each providing either passive or active immunity to SARS-CoV-2 via different immunological mechanisms.

Join us for the sixth in our COVID-19 Webinar Series to discuss:

  • How do these vaccines work? What is their mechanism of action?
  • How do we advance promising therapies through pre-clinical testing and then ensure fast, efficient testing in the clinical setting?
  • What is the most likely timeline for a COVID-19 vaccine from R&D to market access?
  • Most of these therapies will reach the market via accelerated regulatory pathways with limited evidence of efficacy. How do we ensure that they remain safe and effective?

Panelists:

  • Richard Day, (Moderator) Professor of Clinical Pharmacology, University of New South Wales and St Vincent's Hospital, Australia
  • Keith Chirgwin, Deputy Director, Regulatory Affairs, Bill & Melinda Gates Foundation
  • Philip R. Dormitzer, Vice President and Chief Scientific Officer: Viral Vaccines, Pfizer Vaccine Research and Development
  • Julie Gerberding, Executive Vice President and Chief Patient Officer, Merck
  • Joshua Liang, Chief Strategy Officer, Clover Biopharmaceuticals